Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory…
Articles by Joana Carvalho, PhD
First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not…
Taking Xpovio (selinexor) in combination with the steroid dexamethasone leads to promising responses in heavily treated patients…
Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP)…
Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib),…
Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called…
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory…
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide)…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one…